News | September 22, 2010

FDA-Cleared OCT Intravascular Imaging System on Display at TCT

September 22, 2010 - A new intravascular imaging system will be highlighted at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The C7-XR optical coherence tomography (OCT) platform, made by St. Jude Medical, offers physicians a new tool for intravascular lesion assessment.

The system uses near-infrared light to create high-resolution images, allowing physicians to visualize and measure important vessel characteristics that are otherwise invisible or difficult to assess. While fractional flow reserve (FFR) accurately identifies which lesions to stent, OCT-guided treatment can be especially important for assessing stent placement because it shows precisely how the stent is positioned against the artery wall.

In addition to guiding stent selection, the C7-XR System provides physicians with post-stenting information by evaluating the position and deployment of the stent. At follow-up, the technology provides detailed information regarding the inner lining of the vessel and whether there is a reoccurrence of the blood vessel narrowing.

Physicians can learn more about OCT-guided therapy by participating in virtual reality simulations. The simulator enables physicians to manipulate the C7-XR Dragonfly catheter, performing OCT-guided procedures in human-size models and selecting from a variety of case scenarios. The sessions will take place on Sept. 23 and Sept. 24 from 9 a.m. to 5 p.m. and on Sept. 25 from 9 a.m. to 2 p.m. at the St. Jude Medical booth.

St. Jude Medical will also sponsor a scientific symposium entitled, "OCT & FFR, Current Applications, Future Potential." The symposium will take place on Thursday, Sept. 23 from 7 p.m. to 9:30 p.m. in the Renaissance Ballroom, located in the Renaissance Washington, D.C. Downtown Hotel.

For more information: www.sjm.com

Related Content

Philip's co-registration technology showing angiography overlaid with iFR in a coronary vessel segment with a system of dots that show regions where the hemodynamic pressure drops occur. This can aid in identifying culprit lesions. #TCT #TCT2020 #TCTconnect

Philip's co-registration technology showing angiography overlaid with iFR in a coronary vessel segment with a system of dots that show regions where the hemodynamic pressure drops occur. This can aid in identifying culprit lesions.

News | FFR Technologies | October 15, 2020
October 15, 2020 — The one-year results of the late-breaking...
The Philips Healthcare OmniWire is the world’s first solid core fractional flow reserve (FFR) pressure wire for coronary artery interventional procedures.

The Philips Healthcare OmniWire is the world’s first solid core fractional flow reserve (FFR) pressure wire for coronary artery interventional procedures.

News | FFR Technologies | August 18, 2020
August 18, 2020 — Philips Healthcare introduced its new OmniWire, the world’s first solid core...
The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

News | FFR Technologies | July 09, 2020
July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II
The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

Feature | FFR Technologies | July 07, 2020 | Dave Fornell, Editor
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether...
In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image.

In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image. 

Feature | FFR Technologies | August 05, 2019 | Dave Fornell and Greg Freiherr
New technologies have been developed that may replace the traditional pressure wires and adenosine to assess the...
First Prospective Registry Confirms FFR Impacts CAD Treatment Plans
News | FFR Technologies | June 17, 2019
A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans...
One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...